Pancreatic Cancer clinical trials in North Dakota

8 actively recruiting pancreatic cancer trials at 5 sites across North Dakota.

Data from ClinicalTrials.gov · last refreshed 2026-04-20

Phase 3 Recruiting Academic/Other

Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

This phase III trial compares the effect of dose-escalated radiation therapy to usual care in patients with locally advanced unresectable pancreatic ductal adenocarcinoma who have received an initial 4-6 months of chemotherapy. Usual care …

Sponsor: NRG Oncology

NCT ID: NCT06958328

Sites in North Dakota:

Sanford Bismarck Medical Center — Bismarck, North Dakota
Sanford Broadway Medical Center — Fargo, North Dakota
Sanford Roger Maris Cancer Center — Fargo, North Dakota

View on ClinicalTrials.gov →

Phase 2, Phase 3 Recruiting Industry

Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

The primary purpose of this study is to assess the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors.

Sponsor: Exelixis

NCT ID: NCT06943755

Sites in North Dakota:

Exelixis Clinical Site #57 — Fargo, North Dakota

View on ClinicalTrials.gov →

Phase 2 Recruiting NIH

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a pathogenic mutation…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT04858334

Sites in North Dakota:

Sanford Bismarck Medical Center — Bismarck, North Dakota
Sanford Broadway Medical Center — Fargo, North Dakota
Sanford Roger Maris Cancer Center — Fargo, North Dakota

View on ClinicalTrials.gov →

Phase 2 Recruiting Network

Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors

This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors. Chemotherapy drugs, such as capecitabine and temozolomide, work…

Sponsor: SWOG Cancer Research Network

NCT ID: NCT05040360

Sites in North Dakota:

Essentia Health Cancer Center-South University Clinic — Fargo, North Dakota
Essentia Health - Jamestown Clinic — Jamestown, North Dakota

View on ClinicalTrials.gov →

Phase 2 Recruiting Academic/Other

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer

This clinical trial studies the effect of cancer directed therapy given at-home versus in the clinic for patients with cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (adv…

Sponsor: Mayo Clinic

NCT ID: NCT05969860

Sites in North Dakota:

Altru Cancer Center — Grand Forks, North Dakota

View on ClinicalTrials.gov →

Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology

NCT ID: NCT05334069

Sites in North Dakota:

Sanford Bismarck Medical Center — Bismarck, North Dakota
Essentia Health Cancer Center-South University Clinic — Fargo, North Dakota
Sanford South University Medical Center — Fargo, North Dakota
Southpointe-Sanford Medical Center Fargo — Fargo, North Dakota
Sanford Medical Center Fargo — Fargo, North Dakota

View on ClinicalTrials.gov →

Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.

NCT ID: NCT03452774

Sites in North Dakota:

Massive Bio SYNERGY-AI site — Fargo, North Dakota

View on ClinicalTrials.gov →

Recruiting Academic/Other

Integrated Cancer Repository for Cancer Research

The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, h…

Sponsor: University of Nebraska

NCT ID: NCT02012699

Sites in North Dakota:

Essentia Health — Fargo, North Dakota
Trinity Hospital Cancer Care Center — Minot, North Dakota

View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-04-20